Like p16INK4, loss of RB1 function by genetic deletion is commonly seen to be an essential process of oncogenesis in wide ranges of human malignancy, such as retinoblastoma, breast cancer, and small cell carcinoma of the lungs. Here, CDKN2A is linked to breast carcinoma.